Polyclonal antibody that depletes T cells to reduce rejection and GVHD.
Polyclonal anti–T-cell IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent lysis and Fc-mediated ADCC/phagocytosis, producing immunosuppression to reduce rejection and GVHD.
YES
DIRECT
ATG binds CD3 epsilon on T cells and induces complement-dependent lysis and Fc receptor–mediated ADCC/phagocytosis, depleting the target cells.
Polyclonal antibody that depletes T cells to reduce rejection and GVHD.
Polyclonal anti–T-cell IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent lysis and Fc-mediated ADCC/phagocytosis, producing immunosuppression to reduce rejection and GVHD.
YES
DIRECT
Polyclonal IgG binds CD3δ on T cells and triggers complement-dependent lysis and Fc-mediated ADCC/phagocytosis, depleting those cells.
Polyclonal antibody that depletes T cells to reduce rejection and GVHD.
Polyclonal anti–T-cell IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent lysis and Fc-mediated ADCC/phagocytosis, producing immunosuppression to reduce rejection and GVHD.
YES
DIRECT
Anti-thymocyte globulin binds the CD3 complex (including CD3γ) on T cells and induces complement-dependent lysis and Fc receptor–mediated ADCC/phagocytosis, depleting the target cells.
Polyclonal antibody that depletes T cells to reduce rejection and GVHD.
Polyclonal anti–T-cell IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent lysis and Fc-mediated ADCC/phagocytosis, producing immunosuppression to reduce rejection and GVHD.
YES
DIRECT
Polyclonal antibodies bind CD4 on T cells and induce complement-dependent lysis and Fc-mediated ADCC/phagocytosis, depleting CD4+ cells.
Rabbit polyclonal antilymphocyte globulin used for in vivo T-cell depletion to reduce graft-versus-host disease risk.
Rabbit polyclonal IgG against multiple human T‑cell surface antigens (e.g., CD2, CD3, CD4, CD8, HLA) that depletes T lymphocytes via complement-dependent cytotoxicity, Fc-mediated ADCC/phagocytosis, and apoptosis, producing in vivo T‑cell immunosuppression to reduce GVHD risk.
NO
INDIRECT
rATG binds multiple T‑cell antigens (e.g., CD2, CD3, CD4, CD8, HLA) and induces CDC and Fc‑mediated ADCC/phagocytosis/apoptosis. CD29 is not a defined binding target, so CD29 expression alone does not make cells directly killed by rATG.